OnconetixNASDAQ: ONCO

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

Onconetix is in the Healthcare sector

Onconetix is in the Biotechnology industry

Onconetix is headquartered in United States

Onconetix initial public offering (IPO) was on 18 February 2022

https://onconetix.gcs-web.com

No, Onconetix is not included in the S&P 500 index

No, Onconetix is not included in the NASDAQ 100 index

No, Onconetix is not included in the Dow Jones index